Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$118000.0.

  • Ocular Therapeutix's Change in Receivables fell 10548.07% to -$118000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 million, marking a year-over-year decrease of 12799.16%. This contributed to the annual value of -$1.7 million for FY2025, which is 12799.16% down from last year.
  • Per Ocular Therapeutix's latest filing, its Change in Receivables stood at -$118000.0 for Q4 2025, which was down 10548.07% from $356000.0 recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Change in Receivables peaked at $6.2 million during Q2 2023, and registered a low of -$7.2 million during Q1 2025.
  • Its 5-year average for Change in Receivables is $919900.0, with a median of $1.1 million in 2021.
  • Data for Ocular Therapeutix's Change in Receivables shows a peak YoY increase of 1176666.67% (in 2025) and a maximum YoY decrease of 205286.1% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Change in Receivables stood at $1.6 million in 2021, then fell by 3.79% to $1.5 million in 2022, then surged by 70.06% to $2.6 million in 2023, then decreased by 16.87% to $2.2 million in 2024, then crashed by 105.48% to -$118000.0 in 2025.
  • Its last three reported values are -$118000.0 in Q4 2025, $356000.0 for Q3 2025, and $5.2 million during Q2 2025.